.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Harvard Business School
Express Scripts
Chinese Patent Office
UBS
Farmers Insurance
Moodys
US Army
US Department of Justice
Deloitte

Generated: September 26, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,674,799 protect, and when does it expire?


Patent ► Subscribe protects OXYCONTIN and is included in one NDA. There have been two Paragraph IV challenges on Oxycontin.

This patent has one hundred and fifteen patent family members in thirty-six countries.

Summary for Patent: ► Subscribe

Title:Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Abstract:In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
Inventor(s): Chapman; Robert (North Kingstown, RI), Rider; Lonn S. (Foster, RI), Hong; Qi (Sharon, MA), Kyle; Donald (Newtown, PA), Kupper; Robert (Coventry, RI)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Application Number:11/653,531
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-001Apr 5, 2010RXYesNo► Subscribe► SubscribeYY
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-002Apr 5, 2010RXYesNo► Subscribe► SubscribeYY
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-003Apr 5, 2010RXYesNo► Subscribe► SubscribeYY
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272-005Apr 5, 2010RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,129,248Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone► Subscribe
9,522,919Oxycodone compositions► Subscribe
7,683,072Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone► Subscribe
7,674,800Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone► Subscribe
8,822,6878a,14-dihydroxy-7,8-dihydrocodeinone► Subscribe
7,674,798Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone► Subscribe
9,073,933Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)200603738► Subscribe
African Regional IP Organization (ARIPO)2232► Subscribe
Argentina049012► Subscribe
Austria501150► Subscribe
Austria9952► Subscribe
Australia2005230826► Subscribe
Australia2009200335► Subscribe
Australia2011213801► Subscribe
Australia2013202453► Subscribe
Australia2015261590► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Merck
Cantor Fitzgerald
Deloitte
AstraZeneca
Chubb
Daiichi Sankyo
Fuji
US Department of Justice
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot